CH680983C9 - - Google Patents

Download PDF

Info

Publication number
CH680983C9
CH680983C9 CH2906/90A CH290690A CH680983C9 CH 680983 C9 CH680983 C9 CH 680983C9 CH 2906/90 A CH2906/90 A CH 2906/90A CH 290690 A CH290690 A CH 290690A CH 680983 C9 CH680983 C9 CH 680983C9
Authority
CH
Switzerland
Application number
CH2906/90A
Other languages
German (de)
Other versions
CH680983A5 (en]
CH680983C1 (en]
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd Glaxo Wellcome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH680983(C9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd Glaxo Wellcome filed Critical Glaxo Group Ltd Glaxo Wellcome
Publication of CH680983A5 publication Critical patent/CH680983A5/fr
Publication of CH680983C1 publication Critical patent/CH680983C1/xx
Publication of CH680983C9 publication Critical patent/CH680983C9/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CH2906/90A 1989-09-08 1990-09-07 CH680983C9 (en])

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (3)

Publication Number Publication Date
CH680983A5 CH680983A5 (en]) 1992-12-31
CH680983C1 CH680983C1 (en]) 2008-06-25
CH680983C9 true CH680983C9 (en]) 2008-08-15

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2906/90A CH680983C9 (en]) 1989-09-08 1990-09-07

Country Status (20)

Country Link
EP (1) EP0416951B1 (en])
JP (1) JP3042867B2 (en])
AT (1) ATE99941T1 (en])
BE (1) BE1003053A3 (en])
CA (1) CA2024916C (en])
CH (1) CH680983C9 (en])
DE (2) DE19975040I2 (en])
DK (1) DK0416951T3 (en])
ES (1) ES2062392T3 (en])
FR (1) FR2651677B1 (en])
HK (1) HK18695A (en])
HU (1) HU211272A9 (en])
IE (1) IE65535B1 (en])
IL (1) IL95590A (en])
IT (1) IT1241996B (en])
LU (1) LU90392I2 (en])
NL (1) NL990012I2 (en])
NZ (1) NZ235221A (en])
PH (1) PH27594A (en])
SG (1) SG166294G (en])

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
WO2001019342A2 (en) 1999-09-11 2001-03-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
AU2001276497B2 (en) 2000-08-05 2005-04-07 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
ATE396716T1 (de) † 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ATE405275T1 (de) 2002-12-12 2008-09-15 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
WO2005087192A2 (en) * 2004-03-12 2005-09-22 Cipla Limited Salmeterol inhalation formulations
DK1616592T3 (da) 2004-07-16 2011-01-10 Almirall Sa Inhalator til administration af lægemidler i pulverform og en pulverpatron til anvendelse sammen med denne inhalator
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MY178819A (en) 2013-03-15 2020-10-20 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
WO2014177519A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
EP0416951A1 (en) 1991-03-13
ATE99941T1 (de) 1994-01-15
IT9048260A1 (it) 1992-03-07
JP3042867B2 (ja) 2000-05-22
IE65535B1 (en) 1995-11-01
HK18695A (en) 1995-02-17
NZ235221A (en) 1992-11-25
CA2024916C (en) 2002-07-09
IE903256A1 (en) 1991-03-13
NL990012I2 (nl) 1999-09-01
FR2651677B1 (fr) 1993-08-06
DE69005951D1 (de) 1994-02-24
DE69005951T2 (de) 1994-05-26
FR2651677A1 (fr) 1991-03-15
DK0416951T3 (da) 1994-02-14
CH680983A5 (en]) 1992-12-31
LU90392I2 (fr) 1999-06-28
NL990012I1 (nl) 1999-07-01
JPH03167120A (ja) 1991-07-19
BE1003053A3 (fr) 1991-11-05
IL95590A (en) 1996-06-18
DE19975040I2 (de) 2006-07-13
CA2024916A1 (en) 1991-03-09
HU211272A9 (en) 1995-11-28
ES2062392T3 (es) 1994-12-16
IT9048260A0 (it) 1990-09-07
EP0416951B1 (en) 1994-01-12
CH680983C1 (en]) 2008-06-25
IL95590A0 (en) 1991-09-16
IT1241996B (it) 1994-02-02
PH27594A (en) 1993-08-31
SG166294G (en) 1995-06-16

Similar Documents

Publication Publication Date Title
FR2644053B2 (en])
CH680983C9 (en])
EP0708558A3 (en])
FR2644594B1 (en])
FR2646796B1 (en])
EP0707312A3 (en])
FR2645790B1 (en])
FR2647171B1 (en])
GR3006855T3 (en])
FR2641442B1 (en])
FR2646988B1 (en])
FR2647604B1 (en])
FR2645608B1 (en])
FR2646767B1 (en])
FR2642016B1 (en])
FR2643166B1 (en])
DE3991655T (en])
FR2645979B1 (en])
FR2644392B1 (en])
FR2656386B1 (en])
FR2641888B3 (en])
FR2645491B1 (en])
DE3991748T1 (en])
FR2636293B1 (en])
FR2642612B1 (en])

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate filed

Free format text: OICM-NO 54975/19990329, 19990602

SPCG Supplementary protection certificate granted

Free format text: OICM-NO 54975/19990329, 19990602, EXPIRES:20140329

SPCN Certificates - modification new representative

Spc suppl protection certif: C680983/01

Representative=s name: BRAUNPAT BRAUN EDER AG, CH

NV New agent
PFA Name/firm changed

Owner name: GLAXO GROUP LIMITED

Free format text: GLAXO GROUP LIMITED#6-12 CLARGES STREET#LONDON W1Y 8DH (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH) -TRANSFER TO- GLAXO GROUP LIMITED#GLAXO WELLCOME HOUSE, BERKELEY AVENUE#GREENFORD (MIDDX UB6 0NN) (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH)

PK Correction

Free format text: LE MANDATAIRE A ETE MENTIONNE PAR ERREUR COMME TITULAIRE.

AEN Scope or validity of the patent modified

Free format text: DECLARATION DE RENONCIATION PUBLIEE: 25.06.2008

PK Correction

Free format text: INHABER + VERTRETER KORRIGIERT.

PL Patent ceased
SPCP Certificates - modification of firm

Owner name: GLAXO GROUP LIMITED, GB

Spc suppl protection certif: C680983/01

SPCL Supplementary protection certificate deletion

Spc suppl protection certif: C680983/01